Pfizer reports 39 presentations spanning ten medicines at ASH

Pfizer announced it will present its latest data showcasing advances in the treatment of hemophilia, sickle cell disease, and blood cancers at the 65th American Society of Hematology, or ASH, Annual Meeting and Exposition in San Diego from December 9-12. These data from 39 presentations “represent continued innovation and advancement in hemophilia,” including pivotal findings for Pfizer’s novel anti-tissue factor pathway inhibitor candidate marstacimab and the latest findings on a next-generation investigational treatment for sickle cell disease in GBT021601, the company stated. Pfizer will also present the latest research in blood cancer, including for ELREXFIO, a BCMA-directed bispecific antibody recently approved by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory multiple myeloma, or RRMM, who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. “During ASH, we are pleased to present new clinical and real-world data in multiple myeloma from our broad development program for ELREXFIO, following recent FDA accelerated approval. This includes extended efficacy and safety results from MagnetisMM-3, highlighting sustained clinical efficacy and no new safety signals after 20 months of follow-up. These data continue to support the potential of ELREXFIO as the next standard of care for patients with advanced multiple myeloma,” said Chris Boshoff, Chief Oncology Research and Development Officer and Executive Vice President, Pfizer.